by Richard Daverman, PhD
January 18, 2013 -- Shenzhen Neptunus Bioengineering announced that it has filed an application for a US Phase II clinical trial of Polydatin Injection. Polydatin is a Class I innovative traditional Chinese that aides microcirculation of the blood and is expected to be tested as a treatment for myocardial ischemia, cerebral ischemia, shock and other cardiovascular diseases. More details....
Stock Symbol: (SHE: 000078)
